KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance of 18F-FDG-PET/CT for survival following 1L treatment in PTCL patients.
- Researchers noticed the ability of 18F-FDG-PET/CT to identify high-risk PTCL patients with poor prognosis post-1L treatment; further investigation is ongoing.
An accurate assessment of tumor viability post-first-line (1L) treatment is crucial for predicting treatment outcomes in peripheral T-cell lymphomas (PTCLs). While 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is favored in clinical trials, its real-world impact warrants scrutiny.
Raul Cordoba and his team aimed to ascertain the prognostic significance of 18F-FDG-PET/CT in determining survival 1L treatment in PTCL patients.
They performed an inclusive analysis, conducting a retrospective observational study involving 175 patients diagnosed with PTCL between 2008 and 2013 across 13 Spanish sites.
About 50 patients underwent evaluation with 18F-FDG-PET/CT following 1L therapy: 58% were 18F-FDG-PET/CT-negative, and 42% were 18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of 18F-FDG-PET/CT-negative patients and 80.9% of 18F-FDG-PET/CT-positive patients (P = 0.0037). Median progression-free survival (PFS) and overall survival (OS) were 67 and 74 months for 18F-FDG-PET/CT-negative patients and 5 (P< 0.0001) and 10 months (P< 0.0001), respectively, in 18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; P = 0.001).
The study concluded that 18F-FDG-PET/CT effectively identifies high-risk PTCL patients with poor prognosis and survival post-1L treatment. However, further research is necessary to validate the optimal treatment options for PTCL patients.
The study was sponsored by Takeda Farmacéutica España, S.A.
Source: https://pubmed.ncbi.nlm.nih.gov/38299464/
Cordoba R, Sánchez-García J, Domingo-Domenech E, et al. (2024). “18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.” Expert Rev Hematol. 2024 Jan-Mar;17(1-3):95-100. doi: 10.1080/17474086.2024.2313457. Epub 2024 Feb 7. PMID: 38299464.
